---
edited: 2024-03-02
tags:
---
### T-staging

| T   |                                                            | Stage | Surgery          | Adjuvant                                                            |
| --- | ---------------------------------------------------------- | ----- | ---------------- | ------------------------------------------------------------------- |
| Tis | Tumor invasion: none (tumor in situ                        | 0     |                  |                                                                     |
| T1  | submucosa                                                  | 1     | Curative surgery |                                                                     |
| T2  | muscularis propria                                         | 1     | Curative surgery |                                                                     |
| T3  | subserosa                                                  | 2     |                  |                                                                     |
| T4  | T4a: visceral peritoneum<br>T4b: adjacent tissue or organs | 2     |                  | add if perforation, obstruction, or dissection of < 12 lymph nodes. |

### N-staging
- Histological analysis of 12 removed lymph nodes to accurately define the lymph node status is required for accurate staging

| N   |                                                                |     | Treatment                                 |
| --- | -------------------------------------------------------------- | --- | ----------------------------------------- |
| N0  | no lymph node involvement                                      | 1   |                                           |
| N1  | 1–3 regional lymph nodes                                       | 3   | Curative surgery<br>Adjuvant chemotherapy |
| N2  | N2a: 4–6 regional lymph nodes<br>N2b: ≥ 7 regional lymph nodes | 3   | Curative surgery<br>Adjuvant chemotherapy |


### M-staging

| M   | Stage   |                                                                                                                                                              | Resection after neoadjuvant                                                                                                                                                      | Unresectable (Palliative surgeries)                                                                                                                                                                                                                                  |
| --- | ------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| M0  | 1, 2, 3 | Distant metastases: none (M0)                                                                                                                                |                                                                                                                                                                                  |                                                                                                                                                                                                                                                                      |
| M1  | 4       | M1a: affecting only one organ or site<br>M1b: affecting more than one organ or site<br>M1c: peritoneal metastases (regardless of metastasis to other organs) | Indicated in patients with resectable metastases (e.g., liver and/or lung metastasis)<br>May significantly improve the survival of patients with limited metastatic disease.<br> | Intestinal bypass (e.g., ileocolonic anastomosis, colostomy) or enteral stenting for obstructing/occlusive CRC <br>Tumor resection to manage immediately life-threatening complications, such as complete bowel obstruction, persistent GI bleeding, or perforation. |
### Surgeries
- [[Colectomies]] 
- [[Rectal cancer]] 
### Chemotherapy

| **Chemotherapy Regimens** | **Components**                                                            | Indications                                                                                                                                        |
| ------------------------- | ------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------- |
| FOLFOX                    | - Folinic acid (leucovorin)<br> - 5-fluorouracil (5-FU)<br> - Oxaliplatin | Adjuvant therapy<br> Stage II: High risk T4 patients: Perforated/obstructed cancers, Poorly differentiated cancers, <12 nodes removed<br>Stage III |
| FOLFIRI                   | - Folinic acid (leucovorin)<br> - 5-fluorouracil (5-FU)<br> - Irinotecan  | As neoadjuvant for Stage IV                                                                                                                        |
| CAPOX                     | - Capecitabine<br> - Oxaliplatin                                          |                                                                                                                                                    |
| **Biologics**             |                                                                           |                                                                                                                                                    |
| Anti-VEGF antibodies      | - Bevacizumab                                                             |                                                                                                                                                    |
| EGFR antibodies           | - Cetuximab                                                               |                                                                                                                                                    |
- Stage I: No adjuvant therapy needed
- Stage II: [[FOLFOX Regiment]]  given for
	- 
- Stage III: Folfox Regimen 6 cycles
- Stage IV: 
	- Neoadjuvant therapy: [[FOLFIRI Regimen]] 6 cycles
	- [[RAS Gene]] Mutation Absent: Wild K-RAS: [[Monoclonal Antibodies]] 
- Neoadjuvants given only in Non-obstructive Colo-rectal cancer with Liver [[Metastasis]]

### Radiation
- Rectal cancer: standard treatment modality in most stages of rectal cancer [9]
- Colon cancer
	- Not a standard modality because of adverse effects on the small intestine leading to enteritis and strictures
	- May be used in palliative care to treat bone and brain metastases

---
